Experimental drug NU-9 shows promise for Alzheimer's and ALS treatment

Experimental drug NU-9 shows promise for Alzheimer's and ALS treatment

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves neuron health in animal models of Alzheimer's disease, according to a new Northwestern University study.

ALS drug effectively treats Alzheimer's disease in new animal study

Experimental drug NU-9 -- a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) -- improves neuron health in animal models of Alzheimer's disease, according to a new study.

University of California, Los Angeles ALS Clinic

Clinic Phone: 310-794-1195Location:  University of California, Los Angeles ALS Clinic 300 Medical Plaza, B-200 Los Angeles, CA 90095 United States See map: Google Maps California US Care Center Type: MDA/ALS Care Center

CREB3 protein identified as potential ALS treatment target

A rare mutation that leads to abnormally high activity of the CREB3 protein is associated with a reduced risk of developing amyotrophic lateral sclerosis (ALS) and people with ALS who carry this mutation progress significantly more slowly and live longer than those who don’t. That’s according to the study, “CREB3 gain of function variants protect against ALS,” which was published in Nature Communications.  The findings imply “that boosting CREB3…

Kaempferol shows promise for ALS and dementia treatment

A naturally occurring compound, kaempferol, found in fruits and vegetables such as kale, berries, and endives, is under investigation for its potential neuroprotective effects. Research conducted at the University of Missouri suggests that kaempferol may support nerve cell health, offering a possible…

ALS drug effectively treats Alzheimer’s disease in new animal study

Experimental drug NU-9 — a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) — improves neuron health in animal models of Alzheimer’s disease, according to a new Northwestern University study.